Laboratory aspirin resistance reversibility in diabetic patients: a pilot study using different pharmaceutical formulations
R Grimaldi, M Bisi, E Lonni, E Beggiato… - … drugs and therapy, 2014 - Springer
Purpose Aspirin resistance occurs most frequently in diabetic patients and is associated with
poor prognosis. The purpose of this study was to evaluate the prevalence of aspirin …
poor prognosis. The purpose of this study was to evaluate the prevalence of aspirin …
Dose–effect of irbesartan on cyclooxygenase-2 and matrix metalloproteinase-9 expression in rabbit atherosclerosis
L Li, J Li, J Yi, H Liu, H Lei - Journal of Cardiovascular …, 2018 - journals.lww.com
Irbesartan has previously shown antiatherosclerotic effects on human carotid atherosclerotic
plaques. Our study aimed to assess the dose–effect of irbesartan on cyclooxygenase-2 …
plaques. Our study aimed to assess the dose–effect of irbesartan on cyclooxygenase-2 …
Papain ameliorates monocyte-platelet aggregate formation-mediated inflammatory responses in monocytes by upregulating miRNA-146a transcription
L Jiang, C Xu, Y Zhao, Q Huang, W Yuan, Y Wu, X Fei - Plos one, 2022 - journals.plos.org
Background MicroRNA-146a (miRNA-146a) is a nuclear factor κB (NF-κB)-inducible and
inflammation-sensitive miRNA, while papain elicits anti-inflammatory effects by inhibiting …
inflammation-sensitive miRNA, while papain elicits anti-inflammatory effects by inhibiting …
Lumiracoxib Does Not Affect the Ex Vivo Antiplatelet Aggregation Activity of Low‐Dose Aspirin in Healthy Subjects
J Jermany, J Branson, R Schmouder… - The Journal of …, 2005 - Wiley Online Library
This randomized, double‐blind, placebo‐controlled study evaluated the pharmacodynamic
effects of concomitant low‐dose aspirin and lumiracoxib in healthy subjects. Participants …
effects of concomitant low‐dose aspirin and lumiracoxib in healthy subjects. Participants …
Aspirin resistance and atherothrombosis
SA Gabriel, CB Beteli, RS Tanighuchi… - Brazilian Journal of …, 2007 - SciELO Brasil
Acute coronary syndromes, including stable angina, myocardial infarction, both with and
without ST segment elevation and sudden death are responsible for more than two millions …
without ST segment elevation and sudden death are responsible for more than two millions …
Third Annual World Congress on the Insulin Resistance Syndrome: Atherothrombotic disease
ZT Bloomgarden - 2006 - Am Diabetes Assoc
Diabetes and vascular disease At a symposium cosponsored by the International Society of
Diabetes and Vascular Disease (www. dvdres. com), Peter Grant (Leeds, UK) discussed the …
Diabetes and Vascular Disease (www. dvdres. com), Peter Grant (Leeds, UK) discussed the …
Истинная резистентность и псевдорезистентность к аспирину
АИ Мартынов, ЕВ Акатова, ИВ Урлаева… - Рациональная …, 2013 - cyberleninka.ru
Низкая доза аспирина уменьшает риск развития повторного инфаркта миокарда и
инсульта. Резистентность к аспирину может снизить эффективность лечения, именно …
инсульта. Резистентность к аспирину может снизить эффективность лечения, именно …
[HTML][HTML] Predicting significance of COX-2 expression of peripheral blood monocyte in patients with coronary artery disease
Q Huang, X Fei, S Li, C Xu, C Tu, L Jiang… - Annals of Translational …, 2019 - ncbi.nlm.nih.gov
Background Cyclooxygenase-2 (COX-2) plays an important role in the monocyte-platelet
aggregate (MPA)-medicated inflammatory response and possible coronary artery disease …
aggregate (MPA)-medicated inflammatory response and possible coronary artery disease …
The effect of the expression of angiotensin II on extracellular matrix metalloproteinase inducer (EMMPRIN) in macrophages is mediated via the AT1/COX-2/PGE2 …
L Yang, J Ye, R Guo, H Liu, X Wang, F Qi, C Guo - Inflammation research, 2010 - Springer
Aim To explore the expression of extracellular matrix metalloproteinase inducer (EMMPRIN)
in THP-1 macrophages induced by angiotensin II (Ang II) and the mechanism of EMMPRIN …
in THP-1 macrophages induced by angiotensin II (Ang II) and the mechanism of EMMPRIN …